Report Overview

The Brazil Insulin market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 5% during the forecast period.

Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population. Brazil is one of top 10 countries with the highest number of people with diabetes mellitus (DM), affecting 16.8 million peoples. It is estimated that 7.7 million people (2079 years) in the country have not yet been diagnosed, representing an under-diagnosis rate of 46.0%.

Although insulin has been used in the treatment of diabetes for over 90 years, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.



Market Drivers

Brazil has undergone rapid demographic, nutritional, and epidemiological transitions, which have led to an increase in the prevalence of diabetes in this region. Currently, the youth demographic forms a significant portion of Brazils population. Since type I diabetes affects an individual at a very young age, the presence of a large younger demographic provides significant growth opportunities for vendors in the human insulin drugs market in Brazil.

Technological advancements are expected to be one of the key factors for the growth of the human insulin drugs market size in Brazil during the forecast period.

Major Diabetes Type

Based on diabetes type, the insulin drugs market is bifurcated into type 1 diabetes and type 2 diabetes. In terms of type, the type 2 diabetes segment is anticipated to grow at a faster CAGR because of increasing ageing population of the country.